CompletedPhase 2NCT02503657
Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- MediciNova
- Principal Investigator
- Rebecca Bascom, MDPSU Research, Department of Medicine
- Intervention
- MN-001(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 21-80 years · All sexes
- Timeline
- 2016 – 2022
Study locations (1)
- Penn State University College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02503657 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGPHASE2NCT07572383Advanced Imaging to Assess the Effect of Immunosuppression on Progressive FibrosisPeter Caravan
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGPHASE2NCT06968845A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisRein Therapeutics
- ENROLLING BY INVITATIONNCT06885515Telomeres Length in Israeli Fibrotic ILD PatientsBarzilai Medical Center